COVID-19 may solidify Australian biotech Mesoblast Limited’s position at the forefront of the development of stem cell therapies as FDA-regulated biologic products, giving a potential second use for the company’s lead allogeneic mesenchymal stem cell (MSC) therapy, Ryoncil (remestemcel-L).
Ryoncil is already in position to become the first MSC therapy with FDA approval. A BLA is under review with a 30 September 2020 user fee goal for pediatric steroid-refractory acute graft versus host disease
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?